We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




FDA Clears Complexed PSA Test for Prostate Cancer

By HospiMedica staff writers
Posted on 22 Oct 2000
A complexed prostate specific-antigen (cPSA) test has been cleared by the U.S. More...
Food and Drug Administration (FDA) as an aid in the detection of prostate cancer. The test is designed to be run on the Immunol system of Bayer Diagnostics (Tarrytown, NY, USA).

Serum PSA has proven to be an extremely useful marker for early detetection of prostate cancer and in monitoring patients for disease progression and the effects of treatment. Deaths from prostate cancer are declining and prostate cancer survival rates are increasing. The survival rate for all stages combined has increased from 67%-89% over the past twenty years. This increase is mainly due to increasing awareness of prostate cancer among doctors and the general public and earlier PSA testing.

"We note that recent published literature on this new marker demonstrates that cPSA can replace traditional total PSA testing as an aid in detecting prostate cancer,” said Dr. William Wallen, Ph.D., senior vice president, Bayer Diagnostics.

Gold Member
Blood Gas Analyzer
i-Check200
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Medical Examination & Procedure Light
Vega 80
POC Respiratory/Sore Throat Test
BIOFIRE SPOTFIRE (R/ST) Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.